BioSpace News Archive

Statera Biopharma, Inc. today announced advancement of its next-gen research activities that builds upon the immune modulation activity of STAT-200 on Toll-Like Receptors (TLRs) to improve drug characteristics and clinical benefit beyond opioid receptors.

OKYO Pharma Limited is pleased to announce that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, each of which will represent one or a number of the Company’s ordinary shares of no par value each in the United States.

Keymed Biosciences Inc. is pleased to announce that the shares of the Company have been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect with effect from March 7, 2022, pursuant to the announcement issued by the Shenzhen Stock Exchange.

The European Investment Bank has awarded a €7.5 million loan to Diadem Srl, a company developing the first blood-based prognostic test for the early prediction of Alzheimer’s disease.

Immunovia AB announced that the United States Patent and Trademark Office has issued a Notice of Allowance for the patent application for the IMMray™ PanCan-d test available exclusively from Immunovia, Inc.

OMass Therapeutics announces the establishment of its scientific advisory board, comprising of world-renowned experts across biophysical technologies.

Veristat, a scientific-minded global clinical research organization, announced the expansion and strengthening of its service capabilities by acquiring SFL.

TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy.

Elixirgen Therapeutics, Inc. announced that it has entered into an exclusive three-year research collaboration agreement with Taisho Pharmaceutical Co., Ltd.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial.